BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
BioAge Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.99+0.15 (+3.10%)
Close on Oct 19, 2026
- Market cap
- $223.75M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
82.2%
38M of 46M shares
Institutional holders
151
29 new, 19 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 13 sales
Net sold $7.79M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Benjamin Horowitz | 3,233,170 | 9.00% | 13D (active) | Sep 27, 2024 |
| Bihua Chen | 2,890,605 | 6.51% | 13G (passive) amendment | Mar 31, 2026 |
| Kristen Fortney | 2,704,736 | 7.20% | 13G (passive) amendment | Dec 31, 2025 |
| Cormorant Asset Management, LP | 2,390,605 | 5.38% | 13G (passive) amendment | Jun 30, 2026 |
| Dr. James I. Healy (“Healy”) | 2,304,901 | 6.70% | 13D (active) | Sep 27, 2024 |
| BlackRock, Inc. | 2,236,460 | 5.03% | 13G (passive) | Mar 31, 2026 |
| ADAR1 Capital Management, LLC | 1,937,123 | 5.40% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BIOA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| a16z Capital Management, L.L.C. | 3,233,170 | 7.04% | $79.24M | – | 0.56% |
| BlackRock, Inc. | 2,849,077 | 6.21% | $69.83M | +581,321 | 0.00% |
| Cormorant Asset Management, LP | 2,390,605 | 5.21% | $58.59M | −500,000 | 3.00% |
| Sofinnova Investments, Inc. | 2,293,788 | 5.00% | $56.22M | – | 2.91% |
| Jupiter Topco LLC | 2,144,633 | 4.67% | $52.60M | New | 0.02% |
| Octagon Capital Advisors LP | 1,748,000 | 3.81% | $42.84M | – | 3.85% |
| Ra Capital Management, L.P. | 1,671,648 | 3.64% | $40.97M | +21,000 | 0.36% |
| Mpm Bioimpact LLC | 1,667,661 | 3.63% | $40.87M | New | 2.49% |
| Vanguard Capital Management LLC | 1,544,214 | 3.36% | $37.85M | +189,308 | 0.00% |
| Polar Capital Holdings Plc | 1,072,344 | 2.34% | $26.28M | −60,296 | 0.06% |
| Braidwell LP | 1,033,129 | 2.25% | $25.32M | −167,458 | 0.94% |
| State Street Corp | 1,021,464 | 2.23% | $25.04M | +170,570 | 0.00% |
| Geode Capital Management, LLC | 1,004,264 | 2.19% | $24.62M | +254,998 | 0.00% |
| Sands Capital Ventures, LLC | 786,353 | 1.71% | $19.27M | – | 3.14% |
| Orbimed Advisors LLC | 752,153 | 1.64% | $18.44M | +40,342 | 0.34% |
| D. E. Shaw & Co., Inc. | 742,761 | 1.62% | $18.21M | +43,571 | 0.01% |
| Balyasny Asset Management L.P. | 702,858 | 1.53% | $17.23M | −624,687 | 0.02% |
| Pivotal bioVenture Partners Investment Advisor LLC | 653,374 | 1.42% | $16.01M | – | 5.20% |
| Cosmic Management, LLC | 501,833 | 1.09% | $12.30M | – | 3.22% |
| Stempoint Capital LP | 464,171 | 1.01% | $11.38M | −213,137 | 1.96% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 151 | 38M | 82.2% | 29 / 60 | 40 / 19 | 9M | 3M |
| Q1 2026 | 144 | 35M | 75.6% | 49 / 46 | 27 / 17 | 15M | 3M |
| Q4 2025 | 114 | 24M | 51.6% | 29 / 41 | 24 / 9 | 7M | 5M |
| Q3 2025 | 94 | 21M | 46.6% | 14 / 33 | 20 / 3 | 1M | 1M |
| Q2 2025 | 83 | 21M | 45.2% | 25 / 31 | 9 / 9 | 5M | 4M |
| Q1 2025 | 67 | 20M | 44.2% | 15 / 16 | 18 / 12 | 2M | 1M |
| Q4 2024 | 65 | 20M | 42.8% | 36 / 11 | 11 / 29 | 5M | 7M |
| Q3 2024 | 58 | 21M | 45.6% | 58 / 0 | 0 / 0 | 21M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BIOA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,140,593 | 2.49% | $27.96M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 915,623 | 1.99% | $22.44M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 385,004 | 0.84% | $3.48M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 367,975 | 0.80% | $9.02M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 296,801 | 0.65% | $7.27M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 262,153 | 0.57% | $6.43M | 1.50% | Jun 30, 2026 |
| iShares Biotechnology ETF | 223,345 | 0.49% | $5.47M | 0.06% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 201,860 | 0.44% | $1.82M | 0.04% | Jul 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 171,445 | 0.37% | $4.20M | 0.07% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 155,536 | 0.34% | $2.69M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 155,296 | 0.34% | $2.69M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 142,676 | 0.31% | $2.47M | 0.01% | May 31, 2026 |
| Franklin Biotechnology Discovery Fund | 135,049 | 0.29% | $1.22M | 0.11% | Jul 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 127,778 | 0.28% | $2.21M | 0.12% | May 31, 2026 |
| iShares Micro-Cap ETF | 118,122 | 0.26% | $2.90M | 0.19% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eric Morgen | Chief Operating Officer, Director | 67,225 | 0.15% | Feb 19, 2026 |
| Kristen Fortney | Chief Executive Officer, Director | 976,949 | 2.13% | Feb 19, 2026 |
| Shane Barton | Principal Accounting Officer | 4,290 | 0.01% | Jul 1, 2026 |
| Dov A. Goldstein Md | Chief Financial Officer | 36,575 | 0.08% | Apr 24, 2026 |
| Paul D. Rubin | Chief Medical Officer | 0 | – | Apr 3, 2026 |
| James Healy | Director | 2,304,901 | 5.02% | Jun 12, 2026 |
| Jean Pierre Garnier | Director | – | – | Jun 12, 2026 |
| Vijay Satyanand Pande | Director | 3,233,170 | 7.04% | Jun 12, 2026 |
| Patrick G. Enright | Director | 1,710,589 | 3.73% | Jun 12, 2026 |
| Michael H. Davidson | Director | – | – | Jun 12, 2026 |
| Rekha Hemrajani | Director | 3,000 | 0.01% | Jun 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Shane Barton Principal Accounting Officer | Jun 30, 2026 | Option exercise | +4,290 | $10.85 | $46.55K | 4,290 |
| Shane Barton Principal Accounting Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −20,216 | $25.19 | $509.24K | 0 |
| Shane Barton Principal Accounting Officer | Jun 30, 2026 | Option exercise | +7,861 | $4.38 | $34.43K | 20,216 |
| Shane Barton Principal Accounting Officer | Jun 30, 2026 | Option exercise | +4,065 | $4.30 | $17.48K | 12,355 |
| Shane Barton Principal Accounting Officer | Jun 30, 2026 | Option exercise | +4,000 | $8.39 | $33.56K | 8,290 |
| Shane Barton Principal Accounting Officer | Jun 29, 2026 | Option exercise | +9,301 | $10.85 | $100.92K | 11,933 |
| Shane Barton Principal Accounting Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −42,350 | $25.21 | $1.07M | 0 |
| Shane Barton Principal Accounting Officer | Jun 29, 2026 | Option exercise | +14,198 | $4.38 | $62.19K | 42,350 |
| Shane Barton Principal Accounting Officer | Jun 29, 2026 | Option exercise | +8,958 | $4.30 | $38.52K | 28,152 |
| Shane Barton Principal Accounting Officer | Jun 29, 2026 | Option exercise | +7,261 | $8.39 | $60.92K | 19,194 |
| Dov A. Goldstein Md Chief Financial Officer | Apr 23, 2026 | Option exercise | +3,542 | $4.38 | $15.51K | 36,575 |
| Paul D. Rubin Chief Medical Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −8,820 | $17.81 | $157.08K | 0 |
| Paul D. Rubin Chief Medical Officer | Apr 1, 2026 | Option exercise | +5,437 | $4.11 | $22.35K | 5,437 |
| Paul D. Rubin Chief Medical Officer | Apr 1, 2026 | Option exercise | +3,383 | $6.57 | $22.23K | 8,820 |
| Paul D. Rubin Chief Medical Officer | Mar 2, 2026 | Option exercise | +5,433 | $4.11 | $22.33K | 5,433 |
| Paul D. Rubin Chief Medical Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −7,433 | $20.30 | $150.89K | 0 |
| Paul D. Rubin Chief Medical Officer | Mar 2, 2026 | Option exercise | +2,000 | $6.57 | $13.14K | 7,433 |
| Dov A. Goldstein Md Chief Financial Officer | Mar 1, 2026 | Option exercise | +3,542 | $4.38 | $15.51K | 33,033 |
| Paul D. Rubin Chief Medical Officer | Feb 2, 2026 | Option exercise | +5,433 | $4.11 | $22.33K | 5,433 |
| Paul D. Rubin Chief Medical Officer | Feb 2, 2026 | Option exercise | +2,000 | $6.57 | $13.14K | 7,433 |
| Paul D. Rubin Chief Medical Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −7,433 | $18.75 | $139.37K | 0 |
| Dov A. Goldstein Md Chief Financial Officer | Feb 1, 2026 | Option exercise | +3,541 | $4.38 | $15.51K | 29,491 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 16, 2026 | Option exercise | +3,542 | $4.38 | $15.51K | 25,950 |
| Kristen Fortney Chief Executive Officer, Director | Jan 13, 2026 | Sale(10b5-1 plan) | −233,107 | $18.12 | $4.22M | 976,949 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 13, 2026 | Option exercise | +27,000 | $8.39 | $226.53K | 49,408 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 13, 2026 | Sale(10b5-1 plan) | −8,974 | $18.43 | $165.39K | 40,434 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 13, 2026 | Sale(10b5-1 plan) | −1,923 | $21.08 | $40.54K | 22,408 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 13, 2026 | Sale(10b5-1 plan) | −11,663 | $20.54 | $239.56K | 24,331 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 13, 2026 | Sale(10b5-1 plan) | −4,440 | $19.45 | $86.36K | 35,994 |
| Paul D. Rubin Chief Medical Officer | Jan 2, 2026 | Option exercise | +5,433 | $4.11 | $22.33K | 5,433 |
| Paul D. Rubin Chief Medical Officer | Jan 2, 2026 | Option exercise | +2,000 | $6.57 | $13.14K | 7,433 |
| Paul D. Rubin Chief Medical Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −7,433 | $12.85 | $95.51K | 0 |
| Paul D. Rubin Chief Medical Officer | Dec 9, 2025 | Option exercise | +18,000 | $6.57 | $118.26K | 18,000 |
| Paul D. Rubin Chief Medical Officer | Dec 9, 2025 | Sale(10b5-1 plan) | −18,000 | $12.00 | $216.00K | 0 |
| Paul D. Rubin Chief Medical Officer | Dec 4, 2025 | Sale(10b5-1 plan) | −68,897 | $10.19 | $702.06K | 0 |
| Paul D. Rubin Chief Medical Officer | Dec 4, 2025 | Option exercise | +68,897 | $4.11 | $283.17K | 68,897 |
| Vijay Satyanand Pande Director | Oct 3, 2024 | Buy | +25,306 | $19.90 | $503.59K | 1,119,195 |
| Vijay Satyanand Pande Director | Oct 2, 2024 | Buy | +67,096 | $19.73 | $1.32M | 1,093,889 |
| Vijay Satyanand Pande Director | Oct 1, 2024 | Buy | +126,793 | $19.73 | $2.50M | 1,026,793 |
| Shane Barton Principal Accounting Officer | Sep 27, 2024 | Buy | +2,632 | $18.00 | $47.38K | 2,632 |
| Rekha Hemrajani Director | Sep 27, 2024 | Buy | +3,000 | $18.00 | $54.00K | 3,000 |
| Bihua Chen – | Sep 27, 2024 | Conversion | +1,179,529 | – | – | 1,179,529 |
| Bihua Chen – | Sep 27, 2024 | Buy | +450,000 | $18.00 | $8.10M | 1,629,529 |
| Patrick G. Enright Director | Sep 27, 2024 | Buy | +400,000 | $18.00 | $7.20M | 1,710,589 |
| Patrick G. Enright Director | Sep 27, 2024 | Conversion | +1,310,589 | – | – | 1,310,589 |
| Vijay Satyanand Pande Director | Sep 27, 2024 | Conversion | +655,294 | – | – | 655,294 |
| Vijay Satyanand Pande Director | Sep 27, 2024 | Conversion | +855,972 | – | – | 855,972 |
| Vijay Satyanand Pande Director | Sep 27, 2024 | Conversion | +413,100 | – | – | 1,269,072 |
| Vijay Satyanand Pande Director | Sep 27, 2024 | Buy | +900,000 | $18.00 | $16.20M | 900,000 |
| Vijay Satyanand Pande Director | Sep 27, 2024 | Conversion | +189,609 | – | – | 189,609 |
| James Healy Director | Sep 27, 2024 | Buy | +11,113 | $18.00 | $200.03K | 11,113 |
| James Healy Director | Sep 27, 2024 | Buy | +21,814 | $18.00 | $392.65K | 21,814 |
| James Healy Director | Sep 27, 2024 | Buy | +18,353 | $18.00 | $330.35K | 18,353 |
| James Healy Director | Sep 27, 2024 | Buy | +26,497 | $18.00 | $476.95K | 26,497 |
| James Healy Director | Sep 27, 2024 | Buy | +588,888 | $18.00 | $10.60M | 2,227,124 |
| James Healy Director | Sep 27, 2024 | Conversion | +1,638,236 | – | – | 1,638,236 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shane Barton Officer | Jun 30, 2026 | 20,216 | $509.18K | Jun 30, 2026 | Stock Option Exercise |
| Shane Barton Officer | Jun 29, 2026 | 42,350 | $1.07M | Jun 29, 2026 | IPO Shares |
| Paul D. Rubin Officer | Apr 1, 2026 | 8,820 | $157.08K | Apr 1, 2026 | Option Granted 07/01/2020 |
| Paul D. Rubin Officer | Mar 2, 2026 | 7,433 | $148.88K | Mar 2, 2026 | Option Granted 07/01/2020 |
| Paul D. Rubin Officer | Feb 2, 2026 | 7,433 | $139.37K | Feb 2, 2026 | Option Granted - 07/01/2020 |
| Kristen Fortney 10% Stockholder | Jan 13, 2026 | 233,107 | $4.20M | Jan 13, 2026 | RESTRICTED STOCK PURCHASE |
| Dov A. Goldstein Md Officer | Jan 13, 2026 | 27,000 | $531.83K | Jan 13, 2026 | Option Granted - 04/17/2024 |
| Paul D. Rubin Officer | Jan 2, 2026 | 7,433 | $99.68K | Jan 2, 2026 | Options Granted - 07/01/2020 |
| Paul D. Rubin Officer | Dec 9, 2025 | 18,000 | $216.00K | Dec 9, 2025 | Options Granted - 05/29/2022 |
| Paul D. Rubin Officer | Dec 4, 2025 | 68,897 | $701.91K | Dec 4, 2025 | Option Granted - 07/01/2020 |